HealthMore in Health→
HIV Injections Outperform Daily Tablets for Adolescents, Trial Finds
Key Takeaways
- A UCL-led trial called LATA compared daily HIV tablets with long-acting injections of cabotegravir and rilpivirine in 476 adolescents aged 12–19.
- The trial took place at five clinics in Kenya, South Africa, Uganda and Zimbabwe.
- Injections given every eight weeks kept the virus suppressed more effectively than daily tablets, a stronger result than seen in earlier adult trials.
- Nine out of ten adolescents with HIV live in Africa, where the injectable treatment is not currently accessible.
DE
DT Editorial Team··via medicalxpress.com